Breaking Finance News

Edwards Lifesciences Corp (NYSE:EW) has been downgraded to Hold in a report by Zacks Investment Research today.

Yesterday Edwards Lifesciences Corp (NYSE:EW) traded -0.19% lower at $118.12. The company’s 50-day moving average is $111.58 and its 200-day moving average is $111.24. The last closing price is up -0.88% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time period. 293,326 shares of the stock traded hands, down from an average trading volume of 1,285,820

Zacks Investment Research has downgraded Edwards Lifesciences Corp (NYSE:EW) to Hold in a report released on Thursday June 08, 2017.

Previously on 6/7/2017, Zacks Investment Research reported on Edwards Lifesciences Corp (NYSE:EW) increased the target price from $0.00 to $131.00. At the time, this indicated a possible upside of 0.11%.

See Chart Below

Edwards Lifesciences Corp (NYSE:EW)

Edwards Lifesciences Corp has a 52 week low of $81.12 and a 52 week high of $121.45 with a P/E ratio of 42.25 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 22 brokers have issued a research note on the company. The average stock price target is $117.68 with 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Edwards Lifesciences Corp (NYSE:EW)

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.